Physician

Deepa Gali, MD

According to 2025 Medicare claims, Deepa Gali, MD (NPI: 1376856922) practices rheumatology in the Seattle-Bellevue-Kent, WA market, with the plurality of this provider's patient population coming from King, WA. This provider's primary affiliated billing organization is OVERLAKE ARTHRITIS AND OSTEOPOROSIS CENTER, PLLC (NPI: 1174583728; TIN: 200975161) and primary practice location at 98004-3016. Gali is affiliated with the Valley Medical Group-Renton (ACO ID: A3922), participating under the MSSP model.

Gali's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 230 traditional Medicare patients, billed 26,603 HCPCS/CPT codes, and received $801,705 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 487 prescription claims across 110 beneficiaries totaling $60,362 in drug costs, led by Mycophenolate Mofetil (Mycophenolate Mofetil). Open Payments data shows 119 records totaling $7,787. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $18,033 to $801,705. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	256	364	$18,033
2017	324	637	$39,661
2018	326	633	$40,699
2019	311	552	$38,869
2020	213	617	$33,641
2021	180	407	$36,692
2022	145	269	$25,453
2023	205	2,870	$99,735
2024	230	26,603	$801,705

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	61	262	$33,189
2016	194	612	$276,188
2017	214	878	$476,796
2018	201	989	$683,081
2019	205	871	$783,641
2020	199	713	$695,420
2021	170	866	$816,588
2022	174	559	$659,420
2023	141	655	$699,490
2024	110	487	$60,362

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	99	99	$171
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	42	47	$145
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	155	301	$104
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	151	280	$13
96372	Injection of drug or substance under skin or into muscle	48	138	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Mycophenolate Mofetil	Mycophenolate Mofetil	22	675	$1,264
Prednisone	Prednisone	172	6,083	$941
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	43	2,625	$870
Methotrexate	Methotrexate Sodium	42	2,590	$724
Leflunomide	Leflunomide	12	1,020	$407

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	117	$2,831	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$4,956	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Deepa Gali, MD?

Tedicare shows public-source Medicare data for Deepa Gali, MD (NPI 1376856922), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Deepa Gali, MD have ACO affiliation data?

Deepa Gali, MD is shown with ACO affiliation data for Valley Medical Group-Renton (MSSP, ACO ID A3922).

What billing organization is linked to Deepa Gali, MD?

Deepa Gali, MD is linked to OVERLAKE ARTHRITIS AND OSTEOPOROSIS CENTER, PLLC (billing NPI 1174583728) in the available physician profile data.

Does Deepa Gali, MD have Open Payments data?

Deepa Gali, MD has 119 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.